Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
Acceleron, anemia, Antimicrobial, AOCL, Biden, BRAF, Bristol, Cadila, central, consummated, conversion, delayed, diagnostic, director, DMCC, Emory, erythroid, EUA, fiscal, France, fusion, harnessing, invented, Kingdom, Lagevrio, legislation, long, lump, MPP, neuroendocrine, official, onset, overruled, PAH, PCV, Pharma, play, predominately, preferred, proposal, provisional, provisionally, Reblozyl, receipt, regulation, resupply, role, rolling, Romania, Segluromet, sequential, sotatercept, South, Squibb, Steglujan, stronger, sum, superfamily, Sweden, symptom, tender, topline, transforming, triple, University, unvaccinated, urotherial, Weekly, Welireg, widespread, Zealand
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view